Modified-release hydrocortisone (DuoCort) combines rapid with extended-release hydrocortisone, a modified synthetic derivative of the naturally occurring hormone cortisol. Hydrocortisone binds to the glucocorticoid receptor thus mimicking the natural action of cortisol. Modified-release hydrocortisone is intended for the long-term treatment of AI as a substitute for current glucocorticoid replacement therapy and in clinical trials has been administered orally at 15-40mg once-daily. Most patients also received fludrocortisone at a median dose of 100mg daily.
Liraglutide acts like a hormone the body produces naturally that regulates appetite, known as glucagon-like-peptide (GLP-1). By activating areas of the brain that regulate appetite, liraglutide may decrease feelings of hunger which can lead to lower calorie intake and weight loss. If licensed, liraglutide may improve long-term outcomes for weight management in obese adolescents 12-17 years old who currently have limited treatment options.